

From DEPARTMENT OF BIOSCIENCES AND NUTRITION
Karolinska Institutet, Stockholm, Sweden

POST-TRANSLATIONAL MODIFICATIONS IN MAMMARY GLAND DEVELOPMENT AND MAMMARY TUMOR PROGRESSION

Ting Zhuang



Stockholm 2015

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet.

Printed by Eprint AB

© Ting Zhuang, 2015

ISBN 978-91-7676-102-1

POST-TRANSLATIONAL MODIFICATIONS IN MAMMARY GLAND DEVELOPMENT AND MAMMARY TUMOR PROGRESSION

THESIS FOR DOCTORAL DEGREE (Ph.D.)

This thesis will be defended at RED seminar room, Floor 6, Novum, Huddinge.

Tuesday, November 3rd, 2015 at 9:30

By

Ting Zhuang

Principal Supervisor:

Professor Staffan Strömblad
Karolinska Institutet
Department of Biosciences and Nutrition

Co-supervisor:

Professor Kristian Pietras
Lund University
Department of Laboratory Medicine

Opponent:

Associate professor Janine Erler
University of Copenhagen
Biotech Research & Innovation Centre (BRIC)

Examination Board:

Docent Stephan Teglund
Karolinska Institutet
Department of Biosciences and Nutrition

Docent Theodoros Foukakis
Karolinska Institutet
Department of Oncology-Pathology

Professor Michael Welsh
Uppsala University
Department of Medical Cell Biology

To my dearest family



ABSTRACT

Breast cancer is one of the most common cancers in women. Estrogen receptor α (ER α) signaling and p53 signaling have important roles in breast cancer progression. Therefore, post-translational modifications of ER α and p53 play critical roles in breast cancer. The overall aim of this thesis is to characterize the role of RING-finger protein 31 (RNF31) on ER α and p53 signaling and the function of P21-activated kinase 4 (PAK4) on ER α signaling. Moreover, the role of PAK4 in mouse mammary development and mammary tumor progression was also analyzed.

In the first study, RNF31 was shown to active and stabilize ER α , and subsequently to increase estrogen-stimulated cell proliferation in breast cancer cells. In breast cancer clinical databases, the gene expression of RNF31 and ER α target genes were correlated. The suggested mechanism is that RNF31 interacts ER α via the RBR domain and facilitate ER α mono-ubiquitination.

In the second study, RNF31 depletion was shown to increase the gene expression of p53 target genes. RNF31 depletion caused cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner in breast cancer cells. Depletion of RNF31 increased p53 protein levels and the mRNA levels of its downstream target genes. The suggested mechanism is that RNF31 interacts with the p53/MDM2 complex and stabilizes MDM2 and consequently facilitates p53 poly-ubiquitination and degradation.

In the third study, high PAK4 expression level was correlated with poor tamoxifen response in breast cancer patients in clinical databases, based on analysis of available mRNA expression. In MCF-7 cells, PAK4 overexpression promoted tamoxifen resistance, while PAK4 inhibition sensitized tamoxifen-resistant breast cancer cells to tamoxifen. Mechanistically, we identified a regulatory positive feedback loop, where PAK4 acts as a downstream target gene of ER α ; while PAK4 can phosphorylate ER α at Ser305, thereby increasing ER α protein stability and activating ER α signaling. In conclusion, PAK4 may be a suitable target for tamoxifen resistance in breast cancer.

In the fourth study, we elucidated the function of PAK4 in mammary development and mammary tumor progression *in vivo*. We observed no difference in mammary gland development between control mice and PAK4 conditional knockout mice. To test the role of PAK4 in mammary tumor development, conditional depletion of PAK4 was introduced in the MMTV-PyMT breast cancer mouse model. Importantly, conditional PAK4 depletion caused an increased tumor latency in MMTV-PyMT mice, indicating a role for PAK4 in early mammary tumor development.

LIST OF SCIENTIFIC PAPERS

- I. J Zhu, C Zhao, A Kharman-Biz, **T Zhuang**, P Jonsson, N Liang, C Williams, C-Y Lin, Y Qiao, K Zendehdel, S Strömblad, E Treuter, K Dahlman-Wright. The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation. *Oncogene* 01/2014; DOI:10.1038/onc.2013.573; 33(4340-4351).
- II. Jian Zhu, Chunyan Zhao, **Ting Zhuang**, Philip Jonsson, Cecilia Williams, Staffan Strömblad, Karin Dahlman-Wright. RING finger protein 31 (RNF31) promotes p53 degradation in breast cancer cells. *Oncogene* 07/2014; DOI: 10.1038/onc.2015.260.
- III. **Ting Zhuang***, Jian Zhu*, Zhilun Li, Julie Lorent, Karin Dahlman-Wright, Staffan Strömblad. Pharmacological targeting of p21-activated kinase-4 inhibits estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. (Manuscript)
* Equal contributors
- IV. **Ting Zhuang**, Tania Costa, Parisa Rabieifar, Staffan Strömblad. Increased MMTV-PyMT mammary tumor latency by MMTV-Cre-driven conditional gene depletion of p21-activated kinase 4. (Manuscript)

LIST OF ADDITIONAL PUBLICATIONS (NOT INCLUDED IN THE THESIS)

- I. Yichun Qiao, Chiou-Nan Shiue, Jian Zhu, **Ting Zhuang**, Philip Jonsson, Anthony P H Wright, Chunyan Zhao, Karin Dahlman-Wright: AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNF α -induced epithelial-mesenchymal transition in triple-negative breast cancer. *Oncotarget*, 2015. 6(10): p. 7804-14.

CONTENTS

1	Introduction	7
1.1	Neoplasm	7
1.2	Breast cancer.....	8
1.2.1	Epidemiology	8
1.2.2	Pathophysiology	9
1.2.3	Breast cancer categories.....	9
1.2.4	Current treatments and therapeutic challenges.....	12
1.3	P21-activated kinase 4.....	12
1.3.1	Small GTPases and the p21-activated kinase family	12
1.3.2	PAK4 structure and function	13
1.4	Ring-finger protein 31	15
1.4.1	Ubiquitination.....	15
1.4.2	RNF31 structure and function.....	16
1.5	Estrogen receptor alpha.....	16
1.5.1	Estrogen receptor alpha signaling.....	16
1.5.2	ER α in breast cancer	17
1.6	P53	18
2	Aims.....	20
3	Materials and methods	21
3.1	Cells	21
3.2	Xenografts.....	21
3.3	Genetically engineered mice	22
4	Results and discussion.....	24
4.1	Paper I	24
4.2	Paper II.....	25
4.3	Paper III	27
4.4	Paper IV	28
5	Conclusions and future perspectives.....	30
6	Acknowledgements	32
7	References	34

LIST OF ABBREVIATIONS

2D	Two-dimensional
ACK	Activated Cdc42-associated kinase
ARF	ADP-ribosylation factor
BAD	Bcl-2-associated death promoter
BCL-2	B-cell lymphoma 2
Cdc42	Cell division control protein 42 homolog
CK	Cytokeratin
DBD	DNA-binding domain
DCIS	Ductal carcinoma in situ
DNA	Deoxyribonucleic acid
DUB	Deubiquitinating enzyme
E1	Ubiquitin-activating enzyme
E2	Ubiquitin-conjugating enzyme
E2	17 β -estradiol
E3	Ubiquitin ligase
ECM	Extracellular matrix
EGFR	Epidermal growth factor receptor
ER α	Estrogen receptor alpha
ERK	Extracellular signal-regulated kinase
FAK	Focal adhesion kinase
FL	Floxed
GAP	GTPase-activating protein
GDI	Guanine nucleotide dissociation inhibitor
GDP	Guanosine diphosphate
GEF	Guanine nucleotide exchange factor
GEM	Genetically engineered mouse
GTP	Guanosine triphosphate
HDM2	Human double minute clone 2
HECT	Homologous to the E6-AP Carboxyl Terminus
HER2	Human epidermal growth factor receptor 2
HOIP	HOIL-1-interacting protein
IBD	Integrin binding domain

IBR	In-Between-RING
IDC	Invasive ductal carcinoma
IKK γ	I κ B kinase subunit gamma
ILC	Invasive lobular carcinoma
JNK	c-Jun N-terminal kinase
LBD	Ligand-binding domain
LUBAC	Linear ubiquitin assembly complex
MDM2	Murine double minute clone 2
MEK	Mitogen-activated protein kinase kinase
MLK	Mixed-lineage kinase
MMTV-LTR	Mouse mammary tumor virus long terminal repeat
MRCK	Myotonic dystrophy kinase-related Cdc42-binding kinase
mRNA	Messenger RNA
MT	Metallothionein
NF κ B	Nuclear factor kappa-light-chain-enhancer of activated B cells
NES	Nuclear export signal
NLS	Nuclear localization signal
NR	Nuclear receptor
PAK	p21-activated kinase
PBD	p21-GTPase binding domain
PDK	Pyruvate dehydrogenase kinase
PR	Progesterone receptor
PTEN	Phosphatase and tensin homolog
PUB	Putative ubiquitin binding domain
PyMT	Polyoma virus middle T antigen
Ran	Ras-related nuclear protein
Ras	Rat sarcoma viral oncogene homolog
RBCK1	RBCC protein interacting with PKC 1
RBR	RING-In-Between-RING
REG	Regulatory domain
RING	Really interesting new gene
RNF31	RING-finger protein 31
ROCK	Rho-associated protein kinase

Ser	Serine
SERM	Selective estrogen receptor modulator
SH3	SRC homology 3
SHARPIN	Shank-associated RH domain-interacting protein
TAD	Transactivation domain
TGFβ	Transforming growth factor beta
TET	Tetramerization domain
Tet	Tetracycline
TNBC	Triple negative breast cancer
UBA	Ubiquitin binding associated domain
WAP	Whey acidic protein
ZNF_RBZ	Zinc finger domain in Ran-binding proteins domain

1 INTRODUCTION

1.1 NEOPLASM

The word “Neoplasm” came from Ancient Greek (neo means “new” and plasma means “formation”), which refers to the tissue having abnormal appearance, abnormal proliferation pattern and undergoing some form of mutation. In most cases, neoplasm forming a mass, it is commonly called tumor or solid tumor; but in few cases, neoplasm does not form a mass, such as in leukemia. The word “tumor” is of Latin origin and means “swelling”. It is noteworthy that, “tumor” is not only referring to “neoplasm”, but also referring to general mass. However, the two words are used as synonyms in daily clinical work.

Neoplasia describes the state of neoplasm growth. The type of proliferation in neoplasia is called neoplastic proliferation, as the cells do not die as they should and divide more quickly, forming tissue without normal function. In contrast to this term, non-neoplastic proliferation is more common in response to inflammation, tissue damage and repair, etc. It is usually occurring according to a physiological requirement and the formed tissue is mature and functional. This kind of proliferation is under control and will be stopped when the initial factor is removed. The proliferating cells are a polyclonal population, which comes from different parental cells. Compared to non-neoplastic proliferation, neoplastic proliferation has several unique characteristics: 1. Neoplastic proliferation is not coordinated with the body, and is harmful to the body. 2. Neoplastic proliferation is monoclonal. A cell population originates from one neoplastic transformed parental cell, which is a phenomenon called neoplasia clonality. 3. In neoplastic proliferation, the cell morphology, metabolism, function, and differentiation are abnormal. 4. In neoplastic proliferation, the cells have relative autonomy. The growth is rapid and out of control. Even if the initial factors have been removed, the proliferation effect cannot be eliminated, because of the gain-of-function oncogenes and/or the loss-of-function tumor suppressor genes, which can be passed on to the offspring cells.

There are benign and malignant neoplasms. Benign neoplasms usually grow slower and have no capability to invade into the surrounding tissues or metastasize to other parts of the body. Benign neoplasms are usually not fatal unless vital organs are pressed, such as brainstem compression. In contrast, malignant neoplasms grow faster and have the capability to invade the surrounding tissues and to metastasize to distant organs. Metastasis is the main course of death from malignant neoplasms. Actually, benign and malignant neoplasms are not totally black and white, and sometimes there is a grey zone in between. Pre-malignant neoplasms,

which are non-invasive, have the potential to become malignant neoplasms. In clinic, pre-malignant neoplasms are difficult to diagnose and/or to design treatment strategies against.

The malignant neoplasms, also known as cancers, can be divided into different groups, *e.g.* carcinoma, sarcoma, melanoma, lymphoma, leukemia. Carcinomas are the most commonly diagnosed cancers. They are originated from epithelial cells in breasts, lungs, pancreases, and other organs.

1.2 BREAST CANCER

1.2.1 Epidemiology

Breast cancer is one of the most common cancers and the second most common cause of cancer death in women worldwide [1]. Several risk factors of breast cancer have been discovered (Table 1) [2-4].

Table 1. Established and probable risk factor for breast cancer

Factor	High-risk group
Age	Age \geq 55-year-old
Race	White
Geographical location	Developed country
Age at menarche	Menarche before age 11
Age at menopause	Menopause after age 45
Age at first full pregnancy	Age of first childbirth \geq 40-year-old
Family history	Breast cancer in the first-degree relative when young
Previous benign disease	Atypical hyperplasia
Mammographic density	Density \geq 75% of the mammogram
Cancer in another breast	
Socioeconomic group	Group I and II
Lifestyle	
Diet	High intake of saturated fat
Body weight	Body mass index >35
Alcohol consumption	Excessive intake

Smoking	Initiate smoking before first birth
Exposure to ionizing radiation	Abnormal exposure in young female after age 10
Taking exogenous hormones	
Oral contraceptives	Current use
Hormone replacement therapy	Use for ≥ 10 years
Diethylstilbestrol	Use during pregnancy

1.2.2 Pathophysiology

Breast cancers are usually originated from epithelial cells of mammary glands. The carcinogenesis of breast cancer could be due to different molecular events, such as DNA damage and genetic mutations. Each molecular abnormality may lead to the distinct genomic profiling and a different breast cancer subtype. Some individuals with a family history of breast and/or ovarian cancer inherit defects in DNA, such as mutations in BRCA1/2, TP53, or PTEN. An abnormal estrogen exposure can also lead to mutations, which may contribute to the breast cancer formation [5]. Besides the genetic events, the deficiency of immune system also contributes to the development of breast cancer. High activity of proliferation signaling and/or low activity of cell cycle inhibition signaling may affect several cancer cell behaviors, such as cell proliferation, cell survival, cell apoptosis, cell adhesion, and cell motion.

1.2.3 Breast cancer categories

1.2.3.1 Grade

Breast cancer grade indicates the differentiation level. According to tubule formation, nuclear pleomorphism and mitotic count, breast cancer can be classified as low-grade (well differentiated), intermediate-grade (moderately differentiated), and high-grade (poorly differentiated). Lower-grade tumors usually have a better survival rate and can be treated less aggressively; while higher-grade tumors usually link with worse survival rate and require more aggressive medications.

1.2.3.2 Stage

Breast cancer stage indicates the overall distribution of the cancer cells in the whole body, which is mostly referenced to make the therapeutic decisions. The TNM staging is the most commonly recommended, and is based on the size of the tumor (T), lymph node involvement (N), and whether the cancer has metastases (M) to obtain the overall stage. Breast cancer

stage scales from 0 to IV, spanning from noninvasive breast cancer, early invasive cancer to locally advanced breast cancer and metastatic breast cancer. The 5-year overall survival decreases from 99% in stage 0 to 24% in stage IV [6].

1.2.3.3 Histopathological classification

Histopathology classification is based on light microscopy observation of biopsy specimen. Most breast cancers are carcinomas. Carcinoma is a type of cancer originating from epithelial cells. Adenocarcinoma is the most common pathological subtype in breast cancers, which refers to a carcinoma featuring glandular-related tissue cytology and gland-related molecular products. The three most common histopathological types stand for three-quarters of breast cancers: Invasive (or infiltrating) ductal carcinoma (IDC) (55%), Ductal carcinoma in situ (DCIS) (13%), and Invasive (or infiltrating) lobular carcinoma (ILC) (5%) [7]. DCIS, also called intraductal carcinoma, is non-invasive, as the cells have not invaded through the basal layer of the ducts into the surrounding breast tissue. DCIS is a pre-cancer and up to 30% of DCIS cases will develop an invasive ductal carcinoma within 10 years after the DCIS diagnosis. An accurate way to predict the transformation from DCIS to invasive carcinoma is still missing. IDC is the most common type of breast cancer. It starts from a milk duct, breaks through the basal layer of the duct, and has the capability to metastasize through lymphatics and blood stream. ILC starts in the glands (lobules) of breast, and breaks through the basal layer of lobules. Also, like IDC, ILC can metastasize to other parts of the body.

1.2.3.4 Clinical-pathological classification

Breast cancer clinical-pathological classification is based on the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [8, 9]. Breast cancers are grouped as hormone receptor-positive (positive for estrogen receptor and progesterone receptor), HER2-positive, triple positive (positive for estrogen receptor, progesterone receptor, and HER2), and triple negative breast cancer (TNBC) (negative for estrogen receptor, progesterone receptor, and HER2). The adjuvant therapy strategies for different groups are diverse. Endocrine therapy is the priority treatment for hormone receptor-positive patients. Trastuzumab is the target treatment for HER2-positive patients. Moreover, triple-negative breast cancer (TNBC) patients mainly use chemotherapy and radiotherapy.

1.2.3.5 Molecular subtype

Genome-wide microarray analysis has been used to classify invasive breast cancer into different groups: Luminal A, Luminal B, normal-like, HER2 type, and basal-like (Table 2) [10-12]. There are also some breast cancers that do not fall into any of these groups, and they can be listed as unclassified. Most of the breast cancers belong to the luminal groups.

Luminal A tumors tend to be tumor grade 1 or 2. Among all these groups, luminal A has the best prognosis [13]. The women in the luminal B group are usually diagnosed in an earlier age than in the luminal A group [14]. The luminal B group patients have a poorer prognosis than the luminal A group, because they tend to have worse tumor grade, larger tumor size, and more lymph node-metastasis [13, 15, 16]. The HER2 type is not equal to HER2 positive breast cancer. The HER2 type tends to be lymph node-positive and high tumor grade. The prognosis of the HER2 type breast cancer is usually worse than any luminal type. Women with HER2 type tumors are often diagnosed at younger ages than those with luminal A or luminal B tumors. Most of the basal-like breast cancers and triple negative breast cancers (TNBC) overlap. However, there are still some basal-like tumors not belonging to TNBC; and also, some TNBC not belonging to the basal-like group. Most of the BRCA1 mutation associated breast cancers are both basal-like and TNBC [17]. The basal-like tumors tend to be very aggressive and usually have a poor prognosis. Normal-like tumors tend to be small and have a good prognosis. There is a dispute about whether normal-like tumors constitute a specific molecular subtype, or if they are just a group of unclassified tumors.

Table 2. Molecular subtypes of breast cancer

Molecular subtypes	Molecular markers	Prevalence
Luminal A	ER+ and/or PR+, HER2-, low Ki67	40%
Luminal B	ER+ and/or PR+, HER2+ (or HER2- with high Ki67)	20%
HER2 type	ER-, PR-, HER2+	10-15%
Basal-like	ER-, PR-, HER2-, cytokeratin 5/6+ and/or EGFR+ Overexpression of CK15, CK17, vimentin and c-kit	15-20%

Normal-like	ER-, PR-, HER2-, cytokeratin 5/6- and EGFR- Expression of CK8/18	10%
-------------	---	-----

1.2.4 Current treatments and therapeutic challenges

Through a century change, the greatest progress of breast cancer treatment has been seen: the revolution of locoregional surgery; the application of adjuvant chemotherapy; the therapeutic exploration of estrogen receptor; the targeting of the human epidermal growth factor receptor complex; the use of neoadjuvant treatment; and the approaches of biology-driven systemic therapies. Surgery usually is the primary therapy for breast cancer. Adjuvant therapy is given after primary therapy to increase the disease-free survival. Neoadjuvant therapy is given before primary therapy, to shrink the tumor for surgery [18]. Neoadjuvant therapy is given in the same manner as adjuvant therapy, including chemotherapy, endocrine therapy, radiation therapy, target therapy (*e.g.* Trastuzumab), or a combination treatment. A commonly used drug in endocrine therapy is tamoxifen, which blocks estrogen receptor activity. ER positive patients benefit from tamoxifen treatment, however, many patients develop tamoxifen resistance over time. Endocrine therapy resistance is a major challenge in the clinic. Loss of ER expression cannot explain all of the resistance. It is urgent for scientists to characterize the resistance mechanisms. Based on such scientific studies, this challenge may be conquered.

1.3 P21-ACTIVATED KINASE 4

1.3.1 Small GTPases and the p21-activated kinase family

The Ras superfamily consists of various families of small GTPases. Small GTPases are a type of monomeric GTP-binding proteins, which are homologous to the alpha subunit of heterotrimeric G-proteins, and usually in the range of 20-25 kDa. They function as hydrolase enzymes to hydrolyze guanosine triphosphate (GTP). They are "molecular switches" – active when GTP is bound and inactive when GDP is bound. Three classical regulators of GTPases are GEFs (guanine nucleotide exchange factors), GAPs (GTPase-activating proteins), and GDIs (guanine nucleotide dissociation inhibitors). Based on structure, sequence and function similarity, the Ras superfamily can be divided into five main families: Ras (mainly for cell proliferation), Rho (mainly for cell morphology), Ran (mainly for nuclear transport), Rab (mainly for vesicle transport), and Arf (mainly for vesicle transport) family GTPases. Among them, only the Ras and Rho families transmit signals from cell-surface receptors. The Rho family GTPases regulate many aspects of cell morphology. There are three heavily studied

members of this family: Rac1 (mainly affects lamellipodia), Cdc42 (mainly affects filopodia), and RhoA (mainly affects stress fibers). The main effectors of these GTPase are PAK, ACK, MLK, MRCK, and ROCK.

The p21-activated kinase (PAK) family is among the most extensively studied effectors of Rac1 and Cdc42. The PAK family consists of six members and can be divided into two groups based on sequence homology: PAK1-3 in group I and PAK4-6 in group II. PAKs are involved in many cellular functions, such as cell proliferation, cell migration, cell survival and cell death [19]. Moreover, they also play critical roles in tumor progression, such as oncogenic transformation, metastasis and angiogenesis [19]. PAKs, especially PAK1 and PAK4, have often been found overexpressed and/or hyperactivated in many different human cancer forms, such as breast cancer, ovarian cancer, colon cancer and prostate cancer [19]. Among them, breast cancer is the most extensively studied cancer for PAKs. Dominant negative PAK1 leads to a significant reduction of the size of MDA-MB-631 xenograft tumors in mice. Interestingly, the transgenic mice with constitutively active PAK1 develop mammary tumors [20]. These results indicate an essential role of PAK1 in breast cancer.

PAKs regulate several cell signaling pathways controlling cancer cell proliferation, survival, invasion, metastasis, angiogenesis, epithelial-mesenchymal transition, and metabolism. First, for cell proliferation, several PAK members positively regulate key cell cycle signaling pathways such as ERK, AKT and WNT in many cancer cell types. In the ERK pathway, PAK1 can phosphorylate c-RAF at S338 and MEK1 at S298 [21]. In a kinase-independent manner, PAK1 scaffold function may also contribute, as the over-expression of kinase-dead PAK1 can activate ERK in the absence of c-RAF S338 phosphorylation [22]. Moreover, PAK1 scaffold function can also facilitate Akt stimulation by PDK1 and contribute recruitment of Akt to the membrane [23]. The phosphorylation of β -catenin by PAK1 at S663 and S675 stabilizes β -catenin and promotes its nuclear localization, which subsequently upregulates its transcriptional activity [24]. PAK4 was shown to have the similar role [25]. Second, several PAK members have been shown to phosphorylate BAD directly or indirectly indicating a regulatory role in apoptosis [26, 27]. Third, both PAK1 and PAK4 can phosphorylate LIM kinase, which subsequently phosphorylates Cofilin, resulting in polymerization of actin filaments thereby promoting cell motility [28, 29].

1.3.2 PAK4 structure and function

PAK4 is the most extensively studied group II PAK. PAK4 was firstly identified as an effector of Cdc42 to induce actin polymerization and the formation of filopodia [30].

Like other PAKs, PAK4 consists of a conserved C-terminal serine/threonine-kinase domain and an N-terminal regulatory domain. Unlike the auto-inhibition of group I PAKs, the group II PAKs are constitutively phosphorylated. However, a recent study found an autoinhibitory pseudosubstrate in the PAK4 N-terminal region (Figure 1) [31, 32]. In the resulting new model of PAK4 regulation, the binding of an SH3 domain to the newly defined autoinhibitory pseudosubstrate leads to the promotion of PAK4 kinase activity [33].




Figure 1. PAK4 protein domain structure.

Besides the Lim kinase, BAD and β -catenin mentioned above, additional PAK4 substrates have been identified, and some of them are shared with other PAKs. For example, PAK4 phosphorylates GEF-H1, consequently reducing RhoA activity [34]. GEF-H1 is also the substrate of PAK1 and PAK2 [35, 36]. Moreover, PAK4 can regulate cell migration by phosphorylating integrin β 5 [37].

PAK4 is highly expressed during development [38]. Although the PAK4 expression is universal, it only has relatively high expression levels in limited adult organs, such as prostate, testis, and colon, and in most of the other adult tissues the expression levels are quite low [30]. Moreover, PAK4 may be involved in cancer progression [39]. For example, PAK4 may play a role in cell transformation, since a constitutively active PAK4 mutant transforms mouse embryonic fibroblasts NIH3T3 cells *in vitro*; dominant-negative PAK4 partially inhibits Ras-induced transformation in NIH3T3 cells [40, 41]; and overexpression of PAK4 makes NIH3T3 cells tumorigenic in athymic mice [42]. PAK4 may also be required for anchorage-independent growth of HCT116 human colon carcinoma cells [40, 41]. Moreover, by phosphorylating BAD, PAK4 can also protect HeLa cells from apoptosis [43]. Importantly, PAK4 is up-regulated in most human cancer cell lines [41], and has also been found overexpressed in several human cancer forms, including breast cancer, colon, esophageal, pancreas, and ovarian cancer [42, 44-46]. High PAK4 expression in ovary cancer is linked to poor patient survival and chemotherapy resistance [45]. In breast cancer cells, PAK4 inhibits cell adhesion [40, 47, 48] and promotes cell migration by inducing α v β 5 mediated breast

cancer cell motility [29, 37, 48-50]. However, the potential role of PAK4 in breast cancer remains largely elusive.

1.4 RING-FINGER PROTEIN 31

1.4.1 Ubiquitination

Ubiquitin is a 76-amino-acid polypeptide (8kDa) that can be covalently conjugated to other substrate proteins through a process called ubiquitination. The attachment of ubiquitin to substrates requires three enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase). As the initial step of ubiquitination, E1 uses ATP hydrolysis energy to attach and activate ubiquitin; then passes this activated ubiquitin to E2. E3 provides platforms for binding of E2 and a selected substrate protein; E3 thereby transfer ubiquitin to the specific substrate. This process may repeat several times to form different types of ubiquitin chains (poly-ubiquitination), and some ubiquitinated proteins can be targeted by the 26S proteasome for degradation [51]. Protein modification with one single ubiquitin is called mono-ubiquitination, and can be a start of a poly-ubiquitination or a separate event [52]. Ubiquitination can be reversed by deubiquitinating enzymes (DUBs) to remove ubiquitin from the substrates.

Humans have approximately 500-1000 different E3 ligases, which can be divided into four families according to the functional domains: HECT, RING-finger, U-box and PHD-finger [53]. Among them, the RING-finger E3 ligase family is the largest. The two most well-known examples in the RING-finger E3 ligase family that have been associated with carcinogenesis are Murine double minute clone 2 (Mdm2) and BRCA1. The human homologue of Mdm2 is also called Hdm2. Mdm2 is found overexpressed in many human cancers. Mdm2 interacts and targets p53 for degradation. Mdm2 has functions in protein ubiquitination, DNA double strand break repair, and gene expression regulation. BRCA1 is a tumor suppressor. BRCA1 mutations are found in around 70% of all familial breast or ovarian cancers [54].

RING-In-Between-RING (RBR) E3 ligase is a subfamily of the RING-finger E3 ligase family. RBR is defined by an RING1-in-between-ring (IBR)-RING2 motif. The RBR family has functions in NF- κ B signaling and nuclear receptor (NR) signaling. Some of the RBR family members are critical in human diseases, such as Parkin in Parkinson's disease, Dolfen in familial amyotrophic lateral sclerosis and ARA54 in prostate cancer.

1.4.2 RNF31 structure and function

RING-finger protein 31 (RNF31), also called HOIL-1-interacting protein (HOIP), is encoded by the RNF31 gene that was first cloned in 2004 [55]. It belongs to the RBR family. Figure 2 shows the RNF31 protein domain structure [56]. The PUB domain binds to cofactors. The ZNF_RBZ domain is related to the ubiquitin binding function. The UBA domain can bind RBCK1 and mediates linear ubiquitination of IKK γ . The RING-IBR-RING domain is the main functional domain in an ubiquitin ligase.



Figure 2. RNF31 protein domain structure. PUB: putative ubiquitin binding domain; ZNF_RBZ: Zinc finger domain in Ran-binding proteins domain; UBA: ubiquitin binding associated domain.

RNF31 is highly expressed in muscle, heart, and testis [56]. RNF31 was originally identified as a muscle-specific tyrosine kinase receptor interacting protein [57]. RNF31 knockout in mice leads to embryonic lethality. In cancer-related studies, RNF31 has been reported to cause cisplatin resistance through ERK and JNK pathways. Moreover, RNF31 can form the linear ubiquitin assembly complex (LUBAC) together with RBCK1 and SHARPIN. This LUBAC can facilitate linear ubiquitination of IKK γ [58].

1.5 ESTROGEN RECEPTOR ALPHA

1.5.1 Estrogen receptor alpha signaling

Estrogen receptor (ER) is a member of the nuclear receptor (NR) superfamily. ER has two main forms, ER α and ER β , which are encoded by the ESR1 and ESR2 genes, respectively. ER α was firstly reported in the 1960's and cloned from MCF-7 cells in 1985 [59, 60]. ER β was cloned in 1996 [61], which will not be discussed in detail here.

ER α protein has 595 amino acids, which consist of four main functional domains: a DNA-binding domain (DBD), a ligand-binding domain (LBD) and two transcriptional activation functions (AF-1 and AF-2) (Figure 3).



Figure 3. ER α protein domain structure. A-F: (A/B) N-terminal regulatory domain: contains the activation function 1 (AF-1), which is hormone-independent. (C) DNA-binding domain (DBD): binds to DNA estrogen response elements. (D) Hinge region: contains nuclear localization sequences and interacts with AP-1. (E)

Ligand binding domain (LBD): contains the activation function 2 (AF-2), which is hormone-dependent. (F) C-terminal domain: the function is not clear.

ER α is activated by estrogen (17 β -estradiol, E2). Upon estrogen binding, the ER α protein can shuttle from cytoplasm into the nucleus to form dimers, which subsequently bind to estrogen response elements in the DNA and active downstream target genes [62].

1.5.2 ER α in breast cancer

Around 70% of breast cancers are ER α positive. The risk of breast cancer is higher in breast tissues with high ER α expression [63]. Given that ER α is the target gene of itself, ER α can exert a positive self-regulation. Moreover, high levels of ER α expression in breast cancer cells can lead to increased E2-independent activity of ER α [64]. ER-positive cancers tend to depend on ER α signaling for cell growth, which makes ER α a suitable target for breast cancer therapy.

For ER-positive breast cancer patients, selective estrogen receptor modulators (SERMs) are standard endocrine treatment. The most common used drug in SERMs is tamoxifen. Tamoxifen shares a similar structure with E2, and acts as a competitive inhibitor of E2 binding to ER α . Unlike SERMs, which can be used for all ages of breast cancer patients, aromatase inhibitors are only used for post-menopausal patients [65]. By suppressing aromatase enzyme activity, aromatase inhibitors block the estrogen production from androgens. In pre-menopausal women, ovarian aromatase is responsible for estrogen synthesis; while in post-menopausal women, aromatase in fat and muscle mainly function to produce circulating estrogen [66]. In the hypothalamic/pituitary feedback loop in pre-menopausal women, lower estrogen levels lead to an up-regulation of aromatase enzymes in the ovary. Therefore, aromatase inhibitors are ineffective in pre-menopausal patients.

The largest challenge of tamoxifen treatment is drug resistance. There are many mechanisms that may contribute to tamoxifen resistance. However, the mechanisms of tamoxifen resistance are not entirely clear. It is known that either loss of ER α function or upregulation of ER α function (or loss of control) can lead to tamoxifen resistance. Tamoxifen resistance has been linked to high expression of ER α co-activators, such as SRC, which can promote ER α transactivation and cell proliferation [67]. Moreover, tamoxifen resistance may also occur due to the cells shifting to depend on other pathways for cell proliferation, such as HER2, EGFR, and NF κ B pathways. In this case, blocking of ER α pathway is not efficient. ER α post-translational modifications also have functions in tamoxifen resistance, such as

phosphorylation. Multiple phosphorylation sites in ER α have been discovered by mass spectrometry on phosphopeptides. Some of them have been detected in breast tumor biopsy samples, such as S118 [68-74], S167 [74, 75], S282 [76, 77], S305 [77], and T311 [76]. There are some phosphorylation sites linked to tamoxifen resistance, such as S104/S106, S167, and S305 [78]. Among these, S305 is the only phosphorylation site that has displayed clinical correlation with tamoxifen resistance. ER α -S305 phosphorylation positive breast cancer patients tend to be resistant to adjuvant tamoxifen treatment, while ER α -S305 phosphorylation negative breast cancers have been linked to a better recurrence-free survival with tamoxifen treatment [79, 80]. Consequently, blocking ER α -S305 phosphorylation may become a new therapy strategy.

1.6 P53

The p53 protein was firstly reported in 1979 [81]. TP53, the human gene that encodes p53, was uncovered in 1984 [82]. p53 was initially believed to be an oncogene, because p53 levels were higher in many tumors compared to normal tissue, and higher in transformed cell lines compare to non-transformed [83, 84]. Until the second half of the 1980s, p53 was amended as a tumor suppressor gene, because it was found inactivated in human cancers and loss of p53 promoted cancer [85, 86]. The history of p53 research over the past 30 years proves that p53 is one of the most extensively studied genes and proteins in the cancer area.

Human p53 protein consists of 393 amino acids and can be divided into three fragments (N-terminal, central core, C-terminal), and each of them corresponding to specific functions (Figure 4) [87]. The N-terminal fragment contains the transactivation domain (binds to transcription factors) and a Src homology 3-like (SH3) domain (interacts with SIN3). SIN3 can protect p53 from degradation. The central core is the DNA-binding domain. The C-terminal contains nuclear localization and export signals (NLS and NES), a regulatory domain and the tetramerization domain.




Figure 4. P53 protein domain structure. TAD: Transactivation domain; SH3: Src homology 3-like domain; NLS: Nuclear localization signal; TET: Tetramerization domain; NES: Nuclear export signal; REG: Regulatory domain.

The regulation of p53 is tightly controlled through several mechanisms, such as transcriptional modifications, translational modifications, post-translational modifications,

and subcellular localization. In unstressed cells, p53 has a short half-life with continuous ubiquitylation and subsequent 26S proteasome degradation. The ubiquitylation is mainly due to the interaction of p53 with MDM2 [88]. This interaction can be disrupted in the cells in situations like DNA damage, oxidative stress, or oncogene activation. When p53 ubiquitylation is suppressed and its half-life thereby increased, the stabilized p53 protein accumulates in the nucleus to form homotetrameric complexes and works as a transcriptional regulator. P53 initiates cellular response through transcriptional modifications of distinct target genes that primarily function to prevent the proliferation of damaged cells. Although P53 is mainly a nuclear protein, p53 also has functions in the cytosol by protein-protein interactions. p53 can translocate to the mitochondria, where it interacts with anti-apoptotic proteins (*e.g.* BCL2 and BCL/X_L) to induce cell apoptosis [89].

The importance of p53 in cancer is illustrated by the fact that p53 is one of the most frequently mutated tumor suppressor genes in most of the human cancers [90]. Mutant p53 may lose functions by several different mechanisms. Compared with wild-type p53, mutant p53 proteins generally increase the intensity of phosphorylation and acetylation at the sites, which contribute to the stabilization effect, and subsequently facilitate accumulation of dysfunctional mutant p53 in the nucleus [87]. In the nucleus, the mutant p53 can form tetrameric complexes together with wild-type p53 and hamper the functions of wild-type p53. In addition to abolishing the tumor suppressor function of wild-type p53, mutant p53 often act as an oncogene with new activities, termed “gain-of-function”, that can contribute to apoptosis resistance, genomic instability, aberrant cell cycle, invasion, and inflammation [91, 92].

As in other cancers, p53 plays important roles in breast cancer. Approximately 31% of breast cancer patients carries p53 mutations [93]. In Luminal A, Luminal B, HER2 type, and basal-like breast cancers, the percentage of mutant p53 contains are 15%, 30%, 75%, and 80%, respectively [16]. This illustrates that breast cancers with lower ER α and worse prognosis tend to more frequently carry p53 mutations.

2 AIMS

The general aim of this thesis is to contribute to the knowledge of breast cancer. The specific aims for each paper are described as following:

- I. To elucidate the role of RNF31 in ER α signaling in breast cancer.
- II. To identify the role of RNF31 in p53 signaling in breast cancer.
- III. To determine the role of PAK4 in ER α signaling in breast cancer.
- IV. To investigate the role of PAK4 in mouse mammary gland development and mammary tumor progression.

3 MATERIALS AND METHODS

Breast cancer is a group of diseases that have different pathology patterns, genomic features, and outcomes. No single model could mimic all aspects of breast cancer. However, it is still necessary to develop new models to contribute to our understanding and therapeutic targeting of breast cancer. There are different breast cancer models, such as cell lines, xenografts and genetically engineered animals. In this section, the advantages and disadvantages of these breast cancer models will be discussed, although some of them were not used in the studies of this thesis.

3.1 CELLS

Cells are the most commonly used models for breast cancer studies, because there are relatively economical, and easily to propagate and culture. For breast cancer research, the commonly used cells are cell lines and primary cells. There are many differences between human breast cancer cell lines and patient primary breast cancer cells [94, 95], such as genomic alterations, suggesting that during the establishment or after a period of growth and several passages, cell characteristics can change and may become quite different from the initial cells. Unlike primary cells, which are usually isolated from primary tumor lesions, most cancer cell lines are isolated from metastasized cells, which are more aggressive. Noteworthy, most cell culture were performed on traditional two-dimensional (2D) plastic. Compared to 2D culture, three-dimensional (3D) cultures are much better for dynamic interactions between cells and extracellular matrix (ECM) [96]. The ECM has also been shown to be an important regulator of cancer cell morphology and behavior [97]. Moreover, normal cell culture is homotypic and lacks many features of tissues, such as blood vessel, and other cell types communication, which is remarkably different from the breast cancer microenvironment. Heterotypic cultures, which culture the tumor cells together with stromal cells, allow more focus on tumor-stromal cells interaction, such as fibroblasts and macrophages.

3.2 XENOGRAFTS

Many cancer cell lines can be cultured as xenografts, which allow us to analyze the tumor formation, progression and metastasis in a lifelike biological system. However, the xenografts are usually performed in immunocompromised mice, with defect immune systems, which are important in tumor pathophysiology. Moreover, for xenografts, cells are usually subcutaneous injected into the flank of the mouse, which is different from mammary gland

microenvironment. In comparison, orthotopic transplantation into the mammary fat pad is more favorable. Also, from non-invasion to invasion tumors, the cancer cells break through the basement membrane. However, the xenograft tumors do not have this histological structure and do not have the restriction of the basement membrane. For metastasis, the xenografts metastasis mostly occur in the lung; while in human, breast cancer can metastasize to the lung, lymph nodes, bone, liver, and brain.

Clinical isolates can also grow as xenografts, which is a preclinical model and a distinct way to expand patient-derived breast cancer tissue [98]. However, because of the difficulty of clinical samples access, the uncertain transplantation efficiency, and the treatment predicting limitation, this technology has not yet been commonly adopted.

3.3 GENETICALLY ENGINEERED MICE

Among genetically engineered breast cancer research models, genetically engineered mouse (GEM) is the most common used model. Genetic modifications in breast cancer GEM models include the loss of tumor suppressor genes (such as Trp53, Brca1, or Pten) or gain of oncogenes (such as Erbb2, Myc, or PyMT). For the tissue specificity of oncogene targeting, special promoters are used, such as mouse mammary tumor virus long terminal repeat (MMTV-LTR), whey acidic protein (WAP), metallothionin (MT), and cytokeratin 14.

Ideally, these promoters should be mammary-specific, but most of them are also expressed in other tissues [99]. Another negative aspect of many of these models is that some promoters, like MMTV and WAP, are hormonally regulated. The expression of these promoters increases during pregnancy and peaks at lactation which may affect tumor etiology [100].

Because most of the breast cancers originate in the mammary gland epithelial cells, the MMTV promoter, which is mainly expressed in mammary gland epithelial cells, is widely used in breast cancer GEM models [101]. This is also the reason why this promoter is used in paper IV study. Advanced genetic modification strategies are used in conditional and inducible GEM, such as Cre/loxP recombinase-mediated gene deletion GEM and tetracycline (Tet)-regulatable transgenes (Tet-Off and Tet-On) GEM. Comparing breast cancer mouse models with human breast cancers, both of them have similar breast cancer oncogenes, multiple genetic mutations, and analogous tumor pathological progression. For sure they also have many differences. Similar with the xenografts, metastasis of breast cancer GEM is also more commonly occurring in the lung; while in human, breast cancer can metastasize to the lung, lymph nodes, bone, liver, and brain. Moreover, mouse mammary tumors have less fibrosis and inflammation as compared to human breast cancers. It is also worth mentioning

that because of the diversity of human breast cancers, no individual GEM can represent this disease perfectly.

In paper IV study of this thesis, we used one of the most extensively studied breast cancer GEM, MMTV-Polyoma virus middle T antigen (MMTV-PyMT), since it shares many properties with human breast tumors. For example, during tumor progression, there is a gradual loss of steroid hormone receptors; and the tumor progression stages (hyperplasia, adenoma, early and late carcinoma) are similar to human breast cancers [102]. Moreover, this mouse model has short latency, high penetrance and a metastatic potential independent of pregnancy. One obvious drawback of this model is that PyMT is not expressed in human breast cancer. However, several critical pathways contributing to carcinogenesis in MMTV-PyMT mice are also altered in human breast cancers. The deletion of c-Src results in a significant inhibition of PyMT tumor initiation, which shows the essential role of the Src kinase in the PyMT mouse model [103]. Another kinase that plays a critical role is focal adhesion kinase (FAK); it has been shown that specific depletion of FAK can reduce tumor metastasis in PyMT mice [104]. The evidence for the importance of TGF β is that blockade of TGF β inhibits mammary tumor metastasis in PyMT mice [105]. Besides the signal pathway analysis, gene expression profiling has indicated that the tumor generated in MMTV-PyMT mice shares features with the luminal subtype of human breast cancer [106].

4 RESULTS AND DISCUSSION

4.1 PAPER I

The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation

Estrogen receptor α (ER α) is a clinically important mediator of proliferation in ER positive breast cancer. Therefore, insight into the molecular mechanisms that control ER α expression and stability are of outmost importance for the understanding of breast cancer.

Upon knocking-down of RNF31 in MCF-7 cells, cell proliferation decreased dramatically in an E2-dependent manner, which mimicked ER α depletion. Further experiments showed that the depletion of RNF31 reduced ER α protein levels, activity and target gene expression levels. This means that RNF31 contributes to ER α pathways.

In patient specimen, RNF31 was expressed at higher levels in breast tumors compared to adjacent breast tissues. Both in RNF31-depletion microarray data of MCF-7 cells and in the TCGA breast cancer patient database, the expression of RNF31 was correlated with ER α -regulated genes.

Further, RNF31 was found to interact with ER α via the RBR domain and facilitate ER α mono-ubiquitination. Immunofluorescence staining showed that the interaction occurred mainly in the cytosol.

In previous studies, RNF31 was shown to form the linear ubiquitin assembly complex (LUBAC) together with RBCK1 and SHARPIN. LUBAC conjugated linear poly-ubiquitin chains to substrates such as IKK γ , which subsequently facilitates NF κ B pathway signaling. Here, we have presented another type of ubiquitin induced by RNF31, which is the mono-ubiquitination on ER α (Figure 5).

There is a large medical need to derive novel therapeutic strategies and targets for breast cancer including novel strategies that modulate estrogen signaling. In this study, we identified such a novel mediator of estrogen signaling that we believe it should be further explored for its potential as a target in breast cancer. This study identified for the first time the E3 ubiquitin ligase RNF31 as a modulator of ER α signaling in human breast cancer cells by a non-transcriptional mechanism, correlating with association and mono-ubiquitination of ER α and enhanced ER α protein stability. Importantly, RNF31 depletion caused the inhibition of

estrogen-dependent cell proliferation, suggesting inhibition of RNF31 as a potential therapeutic strategy in breast cancer.




Figure 5. Hypothetical model for the functional interplay of RNF31 with ER α signaling in breast cancer cells.

4.2 PAPER II

RING finger protein 31 promotes p53 degradation in breast cancer cells

P53 is an important tumor suppressor protein. Wild type p53 function often correlates with good chemotherapy response and good prognosis in cancers. Therefore, insights into the molecular mechanisms that control p53 levels are important for the improvement of breast cancer therapeutics. In this study, we identified such a novel mediator of p53 signaling, which deserves further exploration for its potential as a target in breast cancer.

In the microarray analysis performed in paper I, we found that knocking-down RNF31 in MCF-7 cells significantly upregulated many P53-activated genes. We then put this gene list into the TGCA clinical sample database and found that 50% of the genes also display a negative correlation in clinical data. These data showed that RNF31 might be a suppressor for P53 signaling.

Further experiments showed that RNF31 knockdown in MCF-7 cells promotes p53 protein stability, p53 downstream target genes activity, and p53-dependent G1 cell cycle arrest.

To analyze if RNF31 may function in cell death, we switched to the ZR751 cell line, which also express wild type p53, as MCF-7 cells don't express caspase 3 and are resistant to

cisplatin. In cisplatin treatment, RNF31 depletion induced cell death in a p53-dependent manner.

By depletion of RNF31 in MCF-7 cells, we observed a remarkable change of p53 protein levels without any change on p53 mRNA. This indicates that the regulation of p53 may be caused by a post-translational modification. Later experiments showed that RNF31 associated with the p53/MDM2 complex, and induced p53 poly-ubiquitination in MDM2-dependent manner.

We then studied how RNF31 regulate p53 through MDM2. Through co-overexpression of RNF31 with MDM2 in HEK293 cells, we found that MDM2 was stabilized by RNF31. By an immunoprecipitation ubiquitin assay, we found that RNF31 could reduce MDM2 poly-ubiquitination. This effect was also observed in MCF-7 cells.

In summary, this study identified for the first time the E3 ubiquitin ligase RNF31 as a modulator of p53 signaling. p53 protein could be degraded by a few E3 ligases such as Pirh1, COP1 and P300, and in particular by MDM2. RNF31 protein interacted with the MDM2/p53 complex (Figure 6). In this process, RNF31 stabilized MDM2 by prohibiting its poly-ubiquitination. This amplified the MDM2 effect on p53 and facilitated p53 degradation. This is how RNF31 suppresses p53 pathways in breast cancer cell. Importantly, RNF31 depletion in breast cancer cells caused cell cycle arrest and induced apoptosis in a p53-dependent manner suggesting inhibition of RNF31 as a novel potential therapeutic strategy in breast cancer.




Figure 6. Hypothetical model for the functional interplay of RNF31 with p53 signaling in breast cancer cells.

4.3 PAPER III

P21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells

Resistance to endocrine therapy remains an important clinical issue in breast cancer treatment. This study describes a potential mechanism in tamoxifen resistance, and a potential marker for endocrine therapy response prediction.

PAK4 expression levels were consistently correlated with poor tamoxifen response in both METABRIC and KMPLLOT databases. According to this, we hypothesized that PAK4 might contribute to tamoxifen resistance. Then we tested this hypothesis in human breast cancer cell lines. In MCF-7 cells, PAK4 overexpression promoted tamoxifen resistance. Consistently, the exposure of tamoxifen-resistant MCF-7/LCC2 breast cancer cells to a group II PAK (PAK4, 5, 6) inhibitor, GNE-2861, sensitized these cells to tamoxifen. This indicates that PAK4 may be involved in tamoxifen resistance.

To explore how PAK4 may cause tamoxifen resistance in breast cancer cells, it is necessary to unravel the role of PAK4 in estrogen receptor alpha (ER α) signaling. Interestingly, PAK4 depletion or GNE-2861 treatment decreased ER α protein levels, ER α target gene expression levels and ER α regulated reporter gene activity in MCF-7 cells. PAK4 depletion or GNE-2861 treatment also decreased E2 stimulated cell proliferation in MCF-7 cells.

Further, ER α protein levels were decreased, but with no changes in ER α mRNA levels upon PAK4 depletion. We further found that PAK4 increased ER α stability. Using an *in vitro* protein phosphorylation assay, we found that PAK4 could phosphorylate ER α at Serine 305. Previous experimental and clinical data suggested that ER α Ser305 phosphorylation may contribute to tamoxifen resistance in breast cancer [79, 80, 107-110]. One possible mechanism is that an altered orientation between ER α and its coactivator SRC-1 elevates the ER α transcription activity in the presence of tamoxifen [107, 108]. Also, phosphorylation of ER α Ser305 by PAK1 could trigger a secondary phosphorylation on Ser118, which may also contribute to tamoxifen resistance [110].

Interestingly, we found a positive feed-forward loop between PAK4 and ER α (Figure 7). PAK4 is a novel ER α target gene, and PAK4 in turn stabilized ER α protein and activated ER α pathway signaling. The stabilization and PAK4-mediated activation of ER α -dependent

transcription seems to occur via PAK4-mediated phosphorylation of ER α -Ser305. These results suggest that PAK4 may offer a novel drug target for breast cancer patients with tamoxifen resistance, and GNE-2861 may act as a candidate.




Figure 7. Hypothetical model for the functional interplay of PAK4 with ER α signaling in breast cancer cells.

4.4 PAPER IV

Increased MMTV-PyMT mammary tumor latency by MMTV-Cre-driven conditional gene depletion of p21-activated kinase 4

Given the increased PAK4 expression levels in breast cancer, it is important to elucidate the function of PAK4 in mammary cancer progression *in vivo*. However, the *in vivo* cancer-related functional evidence is so far limited to xenograft models. In this study, transgenic mice have been used to study endogenous mammary tumor development.

Before a transgenic model with PAK4 depletion can be utilized to study cancer, it is critical to assessing role of PAK4 in the development of the normal mammary gland. We first identified the levels of PAK4 gene expression in the mouse mammary glands. PAK4 mRNA is expressed at relatively low level in mammary glands from virgin to pregnancy, but increased during lactation.

Because of the embryonic lethality upon complete PAK4 gene depletion in mice, we have setup a mouse model lacking PAK4 in the mammary epithelium (MMTV-Cre; PAK4^{fl/fl}) using the Cre/loxP system. To test the efficiency of the PAK4 gene depletion in MMTV-Cre;

PAK4^{fl/fl} mice, the PAK4 mRNA was isolated from lactation mice. MMTV-Cre; PAK4^{fl/fl} mice displayed a strong reduction of PAK4 mRNA levels compared to the control mice.

To observe the ductal growth in juvenile and in adult virgin mice as well as the development during pregnancy and lactation, we examined mammary gland whole mounts and hematoxylin and eosin (HE) stainings of the mouse mammary gland tissues. However, we did not find any difference in mammary gland development between control mice and PAK4 conditional knockout mice. To study the function of the mammary gland, progeny nursed by MMTV-Cre; PAK4^{fl/fl} female were found to have the same weight as in the control group during weaning. As Cre is expressed from postnatal day 22 in MMTV-Cre line D mice [111, 112], we conclude that loss of PAK4 from this stage does not cause defects in mammary gland development from juvenile to lactation. The analysis of mammary gland involution after lactation is in progress.

In MMTV-PyMT mice, PAK4 was found highly expressed in tumors compared to the surrounding normal mammary tissue. To test if genetic depletion of PAK4 may affect mammary tumor development and progression, conditional depletion of PAK4 was introduced into transgenic MMTV-PyMT mice, in which the tumors are induced by the polyoma middle T oncoprotein (PyMT). PAK4 depletion efficiency was tested by immunoblot of the mouse samples. By tumor palpation, conditional depletion of PAK4 was found to be associated with increased tumor latency ($P < 0.01$). Mouse mammary gland whole mount stainings also showed that MMTV-Cre; PAK4^{fl/fl}; MMTV-PyMT mice have less lesions compared to the control mice at 12 weeks of age. These results indicate a role for PAK4 in early tumorigenesis. Previous studies have shown that PAK4 may contribute to cell transformation, because in NIH3T3 cells, constitutively activated PAK4 caused cell transformation, while dominant-negative PAK4 partially inhibited Ras-induced cell transformation [40, 41]. Moreover, recent findings by Costa et al in our laboratory indicated a role for PAK4 in cancer cells to stay out of cellular senescence, a process acting as a barrier in early cancer development.

5 CONCLUSIONS AND FUTURE PERSPECTIVES

In paper I and II, we reported novel roles for RNF31 in breast cancer. RNF31 increased ER α protein stability, ER α signaling activity and estrogen-dependent cell proliferation in breast cancer cells. Importantly, we also observed a positive correlation of gene expression between RNF31 and ER α downstream target genes in breast cancer patient databases. The possible mechanism involves mono-ubiquitination modification of RNF31 on the ER α protein. Moreover, we extended our microarray data analysis to explore the negative regulation of RNF31 on p53 signaling. As an atypical E3 ubiquitin ligase, RNF31 increased MDM2 protein stability, and consequently contributed to p53 protein poly-ubiquitination and degradation. A negative correlation in gene expression levels between RNF31 and p53 targets genes was observed in breast cancer patient databases. Functionally, RNF31 depletion increased cell cycle arrest effect and cisplatin-induced apoptosis in a p53-dependent manner in breast cancer cells. These studies together suggest that, RNF31 may constitute a potential therapeutic target for breast cancer.

In paper III and IV, we focused on the role of PAK4 in breast cancer. PAK4 expression was shown to correlate with tamoxifen resistance in two breast cancer clinical databases and to functionally promote tamoxifen resistance in human breast cancer cell lines. Further experiments showed that PAK4 could phosphorylate ER α at Ser305 thereby increasing ER α protein stability and signaling activity. To study the *in vivo* function of PAK4 in breast cancer, we generated PAK4 mammary gland conditional knockout mice. While we did not find any effect of this PAK4 depletion in mammary gland development, the depletion of PAK4 caused the prolonged tumor latency in MMTV-PyMT mice. Together, this may indicate that also PAK4 may be a potential target for breast cancer therapy.

In papers I and II, we showed that RNF31 facilitates ER α mono-ubiquitination and p53 poly-ubiquitination. Other studies also showed that RNF31 can form the linear ubiquitin assembly complex (LUBAC) together with RBCK1 and SHARPIN, which facilitate signal transduction of the NF κ B pathway. It would be very interesting to elucidate the roles of RNF31 for different substrates in a variety of ubiquitin modifications.

In papers I and II, we found that RNF31 plays important roles in breast cancer cells *in vitro*. However, the knowledge of RNF31 function in breast cancer is still limited. There is a lack of *in vivo* RNF31 breast cancer studies. As RNF31 knockout in mice leads to embryonic lethality, RNF31 conditional knockout mice will be a suitable model to analyze the roles of RNF31 in mammary development and tumorigenesis.

In paper I, II and III, the roles of RNF31 and PAK4 were analyzed in ER α -positive cell lines. Endocrine treatment is specific for ER α -positive breast cancer patients, while Trastuzumab is the target treatment for HER2-positive patients. However, there is at present no specific targeted treatment for triple negative breast cancer (TNBC). Also, it may therefore be interesting to examine the potential roles of RNF31 and PAK4 in triple negative breast cancer (TNBC).

In paper III, ER α was found to be a substrate of PAK4. Interestingly, ER α is also a substrate of PAK1. PAK1 and PAK4 are the most extensively studied members among the PAK group I and II, respectively. There is also other substrates shared between PAK1 and PAK4, such as Lim kinase, GEF-H1, BAD, Paxillin, Raf-1, and β -catenin. It will be interesting to elucidate if there are more overlapping substrates between different PAK kinases.

In paper III, a group II PAK inhibitor, GNE-2861, has been used. Inhibitors of both RNF31 and PAK4 are under development. However, none of these has yet been successfully passed any clinical trial. One PAK4 inhibitor (PF-3758309, Pfizer) has been tested in Phase I clinical trials, but was withdrawn by the reason remains undisclosed. An RNF31 inhibitor has been used in a pre-clinical study of diffuse large B-cell lymphoma (DLBCL) [113]. This inhibitor could also be tested in breast cancer in future studies. The exploitation of RNF31 and PAK4 specific inhibitors may offer us another choice to cancer therapeutics.

In paper IV, the role of PAK4 in breast cancer metastasis has not been analyzed, because no lung metastasis has been found in this study. This may be because of the strain specificity or because the endpoint time we set is relatively early. As PAK4 has been shown have important functions in cell adhesion and motility, it would be interesting to use an alternative model to study metastasis *in vivo*.

6 ACKNOWLEDGEMENTS

My studies were performed at the Department of Bioscience and Nutrition, Karolinska Institutet, Stockholm, Sweden (July 2010 to November 2015). I would like to express my deepest gratitude to all my friends and colleagues who have helped me so much during my study.

I would like to express my gratefulness to my supervisor **Professor Staffan Strömblad**, for sharing your invaluable scientific insight and providing constant support during my PhD training. I am thankful for having the opportunity to join such an excellent lab and meet so many wonderful colleagues here.

My gratitude also goes to my co-supervisor **Professor Kristian Pietras**, for enlightening discussions and sharing your incredible knowledge.

I would like to express my gratitude to **Professor Karin Dahlman-Wright**, for giving me the opportunity to collaborate with your excellent lab, as well as for your help, constant support and encouragement.

I am grateful to my mentor **Docent Chunyan Zhao**, I really enjoy our chatting about life and science during lunch time. I appreciate all the support and guidance from you.

I would like to thank China Scholarship Council for the financial support, without which I couldn't have come to Sweden to pursue my PhD.

I thank all the (current and former) lab members in SST group (arrange in alphabetical order): **Wenny An, Jan Peter Axelsson, Ulrich, Berge, Marianne Van Dijk, Sara Göransson, Jianjiang Hu, Gabriela Imreh, Ammad Khan, Alexa Kiss, Jacob Kowalewski, Ylva Linerson, John Lock, Mehrdad Jafari Mamaghani, Miriam Masia-Balague, Andrew Paterson, Uta Rabenhorst, Hamdah Shafqat, Steve Smith, Matthias Spiess, Pablo Hernandez Varas, Yixin Wang, Hongquan Zhang**. I would like to thank specifically: **Dr. Zhilun Li** for nice collaboration, **Helene Olofsson** for all your enthusiastic help, **Tania Fernandes Costa, Miao Zhao** and **Parisa Rabieifar** for nice project discussion, **Dr. Sylvie Le Guyader** and **Dr. Xiaowei Gong** for your encouragement.

I thank the Bionut Jinhua Poker group: **Yumei Diao, Ning Liang, Rongrong Fan, Zhiqiang Huang, Jiyu Guan, Wenbo Dong, Huaxing Wu, Yimeng Yin, Tenghao Zheng**. I will miss all the happiness in these wonderful Jinhua nights.

I would thank my friends in Bionut: **Ling Han, Jiao Hong, Jingwen Wang, Xu You, Yichun Qiao, Min Jia, Xiaoyan Sun, Jianping Liu, Bei Wei, Fangjie Zhu, Mohammad Sharif Hasni, Amirhossein Kharman Biz, Saioa Goni, Ferdous Rahman.** I would like to thank specifically: **Leander Blaas, Lars-Arne Haldosen, Monica Ahlberg, Lenart Nilson, Marie Franzen, Patricia Degnell, Eva Nordlander** for your help.

I am grateful to **Na Wang, Qian Yang, Mingyong Han, Hongchang Shen, Xufeng Zhang,** for all the help when I arrived Sweden 6 years ago. I also would like to thank **Rui Wang, Chen Suo, Yajuan Wang, Lei Xu, Xiaolu Zhang, Bingnan Li, Lidi Xu, Peng Zhang, Hongya Han, Xinyan Miao, Xuan Li, Ning Xu, Juan Du, Qiang Zhang, Ran Ma, Jiangnan Luo, Chengjun Sun, Tianwei Gu, Shuo Liang, Min Guo, Shaohua Xu, Lu Zhang, Jia Guo, Ju Luan, Chiou-Nan Shiue, Li Xu, Jia Sun, Meng Li, Ruiqing Ni, Xiuzhe Wang, Ting Jia, Jian Yan, Jun Wang, Wei Liu, Yao Shi, Bin Zhao, Jiaqi Huang, Zhiwei Liu, Song Huan, Donghao Lv, Jianwei Zhu** for friendship in Stockholm.

And last, but not least I am grateful to **my parents, my parents-in-law, my aunt,** and all other relatives for their love and constant support. I thank my husband **Jian Zhu** for his love, understanding and support. Thank you for helping with experiments during evenings weekends and. You are my best present during my PhD years.

7 REFERENCES

1. Ferlay, J., et al., *Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012*. Int J Cancer, 2015. **136**(5): p. E359-86.
2. McPherson, K., C.M. Steel, and J.M. Dixon, *ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics*. BMJ, 2000. **321**(7261): p. 624-8.
3. Gaudet, M.M., et al., *Active smoking and breast cancer risk: original cohort data and meta-analysis*. J Natl Cancer Inst, 2013. **105**(8): p. 515-25.
4. Boyd, N.F., et al., *Mammographic density and the risk and detection of breast cancer*. N Engl J Med, 2007. **356**(3): p. 227-36.
5. Cavalieri, E., et al., *Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention*. Biochim Biophys Acta, 2006. **1766**(1): p. 63-78.
6. N., H., et al., *SEER Cancer Statistics Review (CSR) 1975-2012*. http://seer.cancer.gov/csr/1975_2012/. National Cancer Institute. Bethesda, MD, 2015.
7. Sinn, H.P. and H. Kreipe, *A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition*. Breast Care (Basel), 2013. **8**(2): p. 149-54.
8. Tang, P., K.A. Skinner, and D.G. Hicks, *Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?* Diagn Mol Pathol, 2009. **18**(3): p. 125-32.
9. Fumagalli, D., et al., *Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?* Crit Rev Oncol Hematol, 2012. **84 Suppl 1**: p. e58-69.
10. Perou, C.M., et al., *Molecular portraits of human breast tumours*. Nature, 2000. **406**(6797): p. 747-52.
11. Hu, Z., et al., *The molecular portraits of breast tumors are conserved across microarray platforms*. BMC Genomics, 2006. **7**: p. 96.
12. Peddi, P.F., M.J. Ellis, and C. Ma, *Molecular basis of triple negative breast cancer and implications for therapy*. Int J Breast Cancer, 2012. **2012**: p. 217185.
13. Cancer Genome Atlas, N., *Comprehensive molecular portraits of human breast tumours*. Nature, 2012. **490**(7418): p. 61-70.
14. Lund, M.J., et al., *Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report*. Cancer, 2010. **116**(11): p. 2549-59.
15. Voduc, K.D., et al., *Breast cancer subtypes and the risk of local and regional relapse*. J Clin Oncol, 2010. **28**(10): p. 1684-91.
16. Miller, L.D., et al., *An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival*. Proc Natl Acad Sci U S A, 2005. **102**(38): p. 13550-5.

17. Hartman, A.R., et al., *Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer*. Cancer, 2012. **118**(11): p. 2787-95.
18. Mauri, D., N. Pavlidis, and J.P. Ioannidis, *Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis*. J Natl Cancer Inst, 2005. **97**(3): p. 188-94.
19. Radu, M., et al., *PAK signalling during the development and progression of cancer*. Nat Rev Cancer, 2014. **14**(1): p. 13-25.
20. Wang, R.A., et al., *PAK1 hyperactivation is sufficient for mammary gland tumor formation*. Oncogene, 2006. **25**(20): p. 2931-6.
21. Slack-Davis, J.K., et al., *PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation*. J Cell Biol, 2003. **162**(2): p. 281-91.
22. Wang, Z., et al., *p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner*. J Biol Chem, 2013. **288**(27): p. 20093-9.
23. Higuchi, M., et al., *Scaffolding function of PAK in the PDK1-Akt pathway*. Nat Cell Biol, 2008. **10**(11): p. 1356-64.
24. Arias-Romero, L.E., et al., *Pak1 kinase links ErbB2 to beta-catenin in transformation of breast epithelial cells*. Cancer Res, 2013. **73**(12): p. 3671-82.
25. Wong, L.E., et al., *p120-catenin is a binding partner and substrate for Group B Pak kinases*. J Cell Biochem, 2010. **110**(5): p. 1244-54.
26. Schurmann, A., et al., *p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis*. Mol Cell Biol, 2000. **20**(2): p. 453-61.
27. Wu, X., et al., *p21 activated kinase 5 activates Raf-1 and targets it to mitochondria*. J Cell Biochem, 2008. **105**(1): p. 167-75.
28. Yang, N., et al., *Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization*. Nature, 1998. **393**(6687): p. 809-12.
29. Dan, C., et al., *Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin*. J Biol Chem, 2001. **276**(34): p. 32115-21.
30. Abo, A., et al., *PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia*. EMBO J, 1998. **17**(22): p. 6527-40.
31. Baskaran, Y., et al., *Group I and II mammalian PAKs have different modes of activation by Cdc42*. EMBO Rep, 2012. **13**(7): p. 653-9.
32. Tse, E.Y. and Y.P. Ching, *The role of p21-activated kinases in hepatocellular carcinoma metastasis*. J Mol Signal, 2014. **9**: p. 7.
33. Ha, B.H., et al., *Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate*. Proc Natl Acad Sci U S A, 2012. **109**(40): p. 16107-12.
34. Callow, M.G., et al., *PAK4 mediates morphological changes through the regulation of GEF-H1*. J Cell Sci, 2005. **118**(Pt 9): p. 1861-72.
35. Kosoff, R., et al., *Pak2 kinase restrains mast cell FcepsilonRI receptor signaling through modulation of Rho protein guanine nucleotide exchange factor (GEF) activity*. J Biol Chem, 2013. **288**(2): p. 974-83.

36. Zenke, F.T., et al., *p21-activated kinase 1 phosphorylates and regulates 14-3-3 binding to GEF-H1, a microtubule-localized Rho exchange factor*. J Biol Chem, 2004. **279**(18): p. 18392-400.
37. Li, Z., et al., *p21-activated kinase 4 phosphorylation of integrin beta5 Ser-759 and Ser-762 regulates cell migration*. J Biol Chem, 2010. **285**(31): p. 23699-710.
38. Qu, J., et al., *PAK4 kinase is essential for embryonic viability and for proper neuronal development*. Mol Cell Biol, 2003. **23**(20): p. 7122-33.
39. Dart, A.E. and C.M. Wells, *P21-activated kinase 4--not just one of the PAK*. Eur J Cell Biol, 2013. **92**(4-5): p. 129-38.
40. Qu, J., et al., *Activated PAK4 regulates cell adhesion and anchorage-independent growth*. Mol Cell Biol, 2001. **21**(10): p. 3523-33.
41. Callow, M.G., et al., *Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines*. J Biol Chem, 2002. **277**(1): p. 550-8.
42. Liu, Y., et al., *The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice*. Mol Cancer Res, 2008. **6**(7): p. 1215-24.
43. Gnesutta, N., J. Qu, and A. Minden, *The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis*. J Biol Chem, 2001. **276**(17): p. 14414-9.
44. Chen, S., et al., *Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification*. Cancer Biol Ther, 2008. **7**(11): p. 1793-802.
45. Siu, M.K., et al., *p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients*. Proc Natl Acad Sci U S A, 2010. **107**(43): p. 18622-7.
46. Kimmelman, A.C., et al., *Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer*. Proc Natl Acad Sci U S A, 2008. **105**(49): p. 19372-7.
47. Wells, C.M., A. Abo, and A.J. Ridley, *PAK4 is activated via PI3K in HGF-stimulated epithelial cells*. J Cell Sci, 2002. **115**(Pt 20): p. 3947-56.
48. Zhang, H., et al., *P21-activated kinase 4 interacts with integrin alpha v beta 5 and regulates alpha v beta 5-mediated cell migration*. J Cell Biol, 2002. **158**(7): p. 1287-97.
49. Li, Z., et al., *Integrin-mediated cell attachment induces a PAK4-dependent feedback loop regulating cell adhesion through modified integrin alpha v beta 5 clustering and turnover*. Mol Biol Cell, 2010. **21**(19): p. 3317-29.
50. Ahmed, T., et al., *A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF*. Cell Signal, 2008. **20**(7): p. 1320-8.
51. Wilkinson, K.D., *Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome*. Semin Cell Dev Biol, 2000. **11**(3): p. 141-8.
52. Sigismund, S., S. Polo, and P.P. Di Fiore, *Signaling through monoubiquitination*. Curr Top Microbiol Immunol, 2004. **286**: p. 149-85.
53. Nakayama, K.I. and K. Nakayama, *Ubiquitin ligases: cell-cycle control and cancer*. Nat Rev Cancer, 2006. **6**(5): p. 369-81.

54. Heemskerk-Gerritsen, B.A., M. Kriege, and C. Seynaeve, *Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers*. JAMA, 2010. **304**(24): p. 2695; author reply 2695-6.
55. Thompson, H.G., et al., *Identification of the protein Zibra, its genomic organization, regulation, and expression in breast cancer cells*. Exp Cell Res, 2004. **295**(2): p. 448-59.
56. Ehrlund, A., et al., *E3 ubiquitin ligase RNF31 cooperates with DAX-1 in transcriptional repression of steroidogenesis*. Mol Cell Biol, 2009. **29**(8): p. 2230-42.
57. Bromann, P.A., et al., *A putative ariadne-like E3 ubiquitin ligase (PAUL) that interacts with the muscle-specific kinase (MuSK)*. Gene Expr Patterns, 2004. **4**(1): p. 77-84.
58. Ikeda, F., et al., *SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis*. Nature, 2011. **471**(7340): p. 637-41.
59. Jensen, E.V., *Mechanism of estrogen action in relation to carcinogenesis*. Proc Can Cancer Conf, 1966. **6**: p. 143-65.
60. Walter, P., et al., *Cloning of the human estrogen receptor cDNA*. Proc Natl Acad Sci U S A, 1985. **82**(23): p. 7889-93.
61. Kuiper, G.G. and J.A. Gustafsson, *The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens*. FEBS Lett, 1997. **410**(1): p. 87-90.
62. Barkhem, T., et al., *Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists*. Mol Pharmacol, 1998. **54**(1): p. 105-12.
63. Shaaban, A.M., et al., *Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression*. Am J Pathol, 2002. **160**(2): p. 597-604.
64. Fowler, A.M., et al., *Altered target gene regulation controlled by estrogen receptor-alpha concentration*. Mol Endocrinol, 2006. **20**(2): p. 291-301.
65. Cummings, S.R., et al., *The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation*. JAMA, 1999. **281**(23): p. 2189-97.
66. Fabian, C.J., *The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer*. Int J Clin Pract, 2007. **61**(12): p. 2051-63.
67. Berns, E.M., et al., *Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer*. Breast Cancer Res Treat, 1998. **48**(1): p. 87-92.
68. Murphy, L., et al., *Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo*. Clin Cancer Res, 2004. **10**(4): p. 1354-9.
69. Murphy, L.C., et al., *Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen*. Clin Cancer Res, 2004. **10**(17): p. 5902-6.
70. Gee, J.M., et al., *Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer*. Endocr Relat Cancer, 2005. **12 Suppl 1**: p. S99-S111.

71. Sarwar, N., et al., *Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression*. Endocr Relat Cancer, 2006. **13**(3): p. 851-61.
72. Kok, M., et al., *Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer*. J Natl Cancer Inst, 2009. **101**(24): p. 1725-9.
73. Chen, M., et al., *Phosphorylation of estrogen receptor alpha at serine 118 is correlated with breast cancer resistance to tamoxifen*. Oncol Lett, 2013. **6**(1): p. 118-124.
74. Yamashita, H., et al., *Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer*. Endocr Relat Cancer, 2008. **15**(3): p. 755-63.
75. Jiang, J., et al., *Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients*. Clin Cancer Res, 2007. **13**(19): p. 5769-76.
76. Skliris, G.P., et al., *A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer*. Endocr Relat Cancer, 2010. **17**(3): p. 589-97.
77. Bostner, J., et al., *Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit*. Breast Cancer Res Treat, 2013. **137**(2): p. 397-406.
78. de Leeuw, R., J. Neefjes, and R. Michalides, *A role for estrogen receptor phosphorylation in the resistance to tamoxifen*. Int J Breast Cancer, 2011. **2011**: p. 232435.
79. Holm, C., et al., *Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer*. J Pathol, 2009. **217**(3): p. 372-9.
80. Kok, M., et al., *PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer*. Breast Cancer Res Treat, 2011. **125**(1): p. 1-12.
81. Lane, D. and L. Crawford, *T antigen is bound to a host protein in SV40-transformed cells*. Nature, 1979.
82. Matlashewski, G., et al., *Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene*. EMBO J, 1984. **3**(13): p. 3257-62.
83. Rotter, V., *p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells*. Proc Natl Acad Sci U S A, 1983. **80**(9): p. 2613-7.
84. DeLeo, A.B., et al., *Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse*. Proc Natl Acad Sci U S A, 1979. **76**(5): p. 2420-4.
85. Wolf, D. and V. Rotter, *Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells*. Proc Natl Acad Sci U S A, 1985. **82**(3): p. 790-4.
86. Baker, S.J., et al., *Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas*. Science, 1989. **244**(4901): p. 217-21.

87. Bode, A.M. and Z. Dong, *Post-translational modification of p53 in tumorigenesis*. Nat Rev Cancer, 2004. **4**(10): p. 793-805.
88. Wade, M., Y.C. Li, and G.M. Wahl, *MDM2, MDMX and p53 in oncogenesis and cancer therapy*. Nat Rev Cancer, 2013. **13**(2): p. 83-96.
89. Chipuk, J.E. and D.R. Green, *Dissecting p53-dependent apoptosis*. Cell Death Differ, 2006. **13**(6): p. 994-1002.
90. Hollstein, M., et al., *p53 mutations in human cancers*. Science, 1991. **253**(5015): p. 49-53.
91. Oren, M. and V. Rotter, *Mutant p53 gain-of-function in cancer*. Cold Spring Harb Perspect Biol, 2010. **2**(2): p. a001107.
92. Solomon, H., S. Madar, and V. Rotter, *Mutant p53 gain of function is interwoven into the hallmarks of cancer*. J Pathol, 2011. **225**(4): p. 475-8.
93. International Cancer Genome, C., et al., *International network of cancer genome projects*. Nature, 2010. **464**(7291): p. 993-8.
94. Ross, D.T., et al., *Systematic variation in gene expression patterns in human cancer cell lines*. Nat Genet, 2000. **24**(3): p. 227-35.
95. Neve, R.M., et al., *A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes*. Cancer Cell, 2006. **10**(6): p. 515-27.
96. Lee, G.Y., et al., *Three-dimensional culture models of normal and malignant breast epithelial cells*. Nat Methods, 2007. **4**(4): p. 359-65.
97. Pickup, M.W., J.K. Mouw, and V.M. Weaver, *The extracellular matrix modulates the hallmarks of cancer*. EMBO Rep, 2014. **15**(12): p. 1243-53.
98. Whittle, J.R., et al., *Patient-derived xenograft models of breast cancer and their predictive power*. Breast Cancer Res, 2015. **17**: p. 17.
99. Jonkers, J. and P.W. Derksen, *Modeling metastatic breast cancer in mice*. J Mammary Gland Biol Neoplasia, 2007. **12**(2-3): p. 191-203.
100. Vargo-Gogola, T. and J.M. Rosen, *Modelling breast cancer: one size does not fit all*. Nat Rev Cancer, 2007. **7**(9): p. 659-72.
101. Hollern, D.P. and E.R. Andrechek, *A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer*. Breast Cancer Res, 2014. **16**(3): p. R59.
102. Fluck, M.M. and B.S. Schaffhausen, *Lessons in signaling and tumorigenesis from polyomavirus middle T antigen*. Microbiol Mol Biol Rev, 2009. **73**(3): p. 542-63, Table of Contents.
103. Guy, C.T., et al., *Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice*. Genes Dev, 1994. **8**(1): p. 23-32.
104. Lahlou, H., et al., *Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression*. Proc Natl Acad Sci U S A, 2007. **104**(51): p. 20302-7.
105. Muraoka, R.S., et al., *Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases*. J Clin Invest, 2002. **109**(12): p. 1551-9.

106. Herschkowitz, J.I., et al., *Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors*. Genome Biol, 2007. **8**(5): p. R76.
107. Zwart, W., et al., *PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1*. EMBO J, 2007. **26**(15): p. 3534-44.
108. Michalides, R., et al., *Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer*. Cancer Cell, 2004. **5**(6): p. 597-605.
109. Bostner, J., et al., *Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer*. Clin Cancer Res, 2010. **16**(5): p. 1624-33.
110. Rayala, S.K., et al., *P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation*. Cancer Res, 2006. **66**(3): p. 1694-701.
111. Robinson, G.W. and L. Hennighausen, *MMTV-Cre transgenes can adversely affect lactation: considerations for conditional gene deletion in mammary tissue*. Anal Biochem, 2011. **412**(1): p. 92-5.
112. Wagner, K.U., et al., *Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice*. Transgenic Res, 2001. **10**(6): p. 545-53.
113. Yang, Y., et al., *Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms*. Cancer Discov, 2014. **4**(4): p. 480-93.